Pieris Non Current Liabilities Total vs Other Liab Analysis
PIRS Stock | USD 10.36 0.04 0.38% |
Pieris Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pieris Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pieris Pharmaceuticals is a good investment. Please check the relationship between Pieris Pharmaceuticals Non Current Liabilities Total and its Other Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.
Non Current Liabilities Total vs Other Liab
Non Current Liabilities Total vs Other Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pieris Pharmaceuticals Non Current Liabilities Total account and Other Liab. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Pieris Pharmaceuticals' Non Current Liabilities Total and Other Liab is 0.97. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Other Liab in the same time period over historical financial statements of Pieris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pieris Pharmaceuticals' Non Current Liabilities Total and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Pieris Pharmaceuticals are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Non Current Liabilities Total i.e., Pieris Pharmaceuticals' Non Current Liabilities Total and Other Liab go up and down completely randomly.
Correlation Coefficient | 0.97 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Non Current Liabilities Total
Other Liab
Most indicators from Pieris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.At this time, Pieris Pharmaceuticals' Issuance Of Capital Stock is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.07 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.37 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 31.4M | 25.9M | 42.8M | 25.4M | Depreciation And Amortization | 3.7M | 8.2M | 1.8M | 1.9M |
Pieris Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Pieris Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pieris Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 141.1M | 105.0M | 153.6M | 95.5M | 38.7M | 36.7M | |
Other Current Liab | 5.0M | 5.5M | 15.8M | 10.7M | 8.6M | 5.7M | |
Total Current Liabilities | 27.0M | 22.1M | 50.6M | 36.6M | 11.9M | 23.7M | |
Total Stockholder Equity | 51.4M | 31.0M | 50.8M | 27.9M | 26.8M | 28.8M | |
Net Debt | (46.0M) | (53.5M) | (103.9M) | (25.5M) | (17.4M) | (18.3M) | |
Retained Earnings | (174.2M) | (211.4M) | (257.1M) | (290.4M) | (315.0M) | (299.2M) | |
Cash | 62.3M | 70.4M | 117.8M | 38.6M | 17.4M | 16.5M | |
Cash And Short Term Investments | 104.2M | 70.4M | 117.8M | 59.2M | 26.4M | 25.0M | |
Common Stock Total Equity | 54K | 55K | 56K | 72K | 82.8K | 42.7K | |
Common Stock Shares Outstanding | 632.8K | 681.0K | 806.8K | 927.2K | 1.1M | 1.4M | |
Liabilities And Stockholders Equity | 141.1M | 105.0M | 153.6M | 95.5M | 38.7M | 36.7M | |
Non Current Liabilities Total | 62.7M | 51.8M | 52.2M | 31.0M | 35.6M | 30.4M | |
Total Liab | 89.7M | 74.0M | 102.8M | 67.6M | 11.9M | 11.3M | |
Total Current Assets | 115.0M | 75.7M | 127.6M | 73.4M | 38.7M | 68.3M | |
Common Stock | 55K | 56K | 72K | 74K | 98K | 53.4K | |
Other Liab | 47.3M | 35.9M | 38.4M | 18.7M | 21.5M | 26.7M | |
Net Tangible Assets | 51.4M | 31.0M | 50.8M | 27.9M | 32.1M | 31.6M | |
Property Plant And Equipment Net | 22.9M | 26.0M | 23.0M | 20.7M | 23.8M | 12.2M | |
Current Deferred Revenue | 11.3M | 12.6M | 25.1M | 20.8M | 23.9M | 17.9M | |
Accounts Payable | 10.1M | 3.0M | 8.6M | 4.2M | 3.4M | 4.0M | |
Non Current Assets Total | 26.1M | 29.3M | 25.9M | 22.1M | 25.4M | 14.6M | |
Other Assets | 910K | 3.1M | 7.2M | 2.9M | 3.3M | 1.8M | |
Net Receivables | 6.8M | 1.7M | 3.3M | 5.8M | 6.0M | 4.4M | |
Retained Earnings Total Equity | (147.1M) | (174.2M) | (211.4M) | (257.1M) | (231.4M) | (219.9M) | |
Short Term Investments | 34.8M | 53.2M | 41.9M | 20.5M | 9.0M | 15.9M | |
Capital Surpluse | 189.9M | 227.5M | 242.7M | 307.0M | 353.0M | 370.7M | |
Other Current Assets | 4.1M | 3.6M | 6.5M | 8.4M | 6.3M | 4.3M | |
Other Stockholder Equity | 227.5M | 242.7M | 307.0M | 318.5M | 341.6M | 214.7M | |
Property Plant And Equipment Gross | 22.9M | 22.0M | 23.0M | 20.7M | 23.8M | 25.0M | |
Accumulated Other Comprehensive Income | (2.0M) | (295K) | 829K | (254K) | 28K | 29.4K | |
Non Current Liabilities Other | 27K | 62.7M | 6K | 52.2M | 60.1M | 63.1M | |
Property Plant Equipment | 19.5M | 26.0M | 23.0M | 20.7M | 23.8M | 25.0M | |
Non Currrent Assets Other | 3.1M | 3.3M | 2.9M | 1.4M | 1.6M | 1.7M | |
Net Invested Capital | 51.4M | 31.0M | 50.8M | 27.9M | 32.1M | 39.0M | |
Net Working Capital | 88.0M | 53.6M | 77.1M | 36.8M | 33.2M | 51.6M | |
Capital Stock | 55K | 56K | 72K | 74K | 85.1K | 68.4K |
Pair Trading with Pieris Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pieris Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pieris Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Pieris Stock
Moving against Pieris Stock
0.71 | JPHLF | Japan Post Holdings | PairCorr |
0.69 | JPSTF | JAPAN POST BANK | PairCorr |
0.5 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
0.47 | HPQ | HP Inc Fiscal Year End 19th of November 2024 | PairCorr |
0.38 | ROIV | Roivant Sciences Financial Report 26th of June 2024 | PairCorr |
The ability to find closely correlated positions to Pieris Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pieris Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pieris Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pieris Pharmaceuticals to buy it.
The correlation of Pieris Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pieris Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pieris Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pieris Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.